In het Parool geeft onze eigen Annemiek Verkamman uitleg over de voordelen die
de vestiging van het Europees Medicijn Agentschap, EMA, in Nederland heeft voor
het nationale life sciences-cluster. Hoewel de VS voorloopt op het gebied van
geneesmiddelontwikkeling, is het Nederlandse gezondheidssysteem beter toegerust
om ervoor te zorgen dat die geneesmiddelen de patiënt daadwerkelijk bereiken. “Dat
biedt kansen voor ons,” aldus Annemiek, “want in het Nederlandse model weten we
elkaar goed te vinden, zodat we tot oplossingen komen waarbij gezondheid,
innovatie en betaalbaarheid samengaan.” In het kielzog van EMA zullen ook meer gespecialiseerde
dienstverleners hun weg naar Nederland vinden om biotechbedrijven te
ondersteunen. “Dat kan ertoe leiden dat de ontwikkeling minder lang hoeft te
duren en er minder mislukkingen zijn.”
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-11-05 18:06:392019-11-05 18:06:41Iedereen wordt beter van komst medicijnagentschap← #nieuws
Afgelopen week vond de jaarlijkse editie van de Dutch Design Week plaats. Net als in eerdere edities, kwam biotechnologie als rode draad terug in verschillende toepassingen, exposities en discussies. Dit leverde interessante perspectieven en ideeën op. Want waar biotechnologie van oudsher in hokjes als geneesmiddelen en planten en industriële toepassingen valt, komen tijdens de Dutch Design Week heel andere benaderingen naar voren. Wat te denken van de bioplastics uit koeienmest waar kunstenaar en ondernemer Jalila Essaïdi aan werkt? Of de ‘levende’ huizen van de toekomst die architect Bob Hendrikx wil ontwikkelen met hulp van biotech.
Benieuwd naar dit laatste project? Lees hier verder op online platform Duurzaam Bedrijfsleven.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-10-29 21:59:402019-10-29 22:29:17Biotech volop in de aandacht tijdens Dutch Design Week← #nieuws
Bij de MSD-locatie in Haarlem ging afgelopen
week de eerste paal de grond in voor een gloednieuw koelmagazijn vlak achter
het huidige exemplaar. Ook start binnenkort de bouw van een laboratorium en een
omvangrijke uitbreiding van de huidige fabrieksruimte. Met de uitbreidingen speelt
MSD in op de snelgroeiende vraag naar vaccins, waarvoor het bedrijf in de
komende 3 tot 5 jaar een verdubbeling van de productie verwacht.
Daarnaast bereidt MSD zich voor op een mogelijke harde Brexit, wat zou betekenen dat in het Verenigd Koninkrijk verpakte medicijnen voor de Europese markt onder andere in Haarlem opnieuw getest moeten worden. Om de medicijnen adequaat te bewaren, is een nieuw koelmagazijn noodzakelijk. MSD is met 1000 werknemers in Haarlem al een van de grootste werkgevers in de regio, maar versterkt deze positie met deze uitbreiding nog verder.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-10-29 21:51:412019-10-29 21:51:43MSD breidt flink uit in Haarlem← #nieuws
Cato Research has merged with Specialized Medical Services-oncology BV (SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year.
By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. Headquartered in Schiphol, the Netherlands, SMS-oncology is one of the few full-service contract research organizations (CROs) in the world dedicated to oncology. The boutique CRO’s deep expertise in designing and executing complex oncology and immuno-oncology trials complements CATO’s regulatory knowledge and drug development services.
“CATO and SMS-oncology bring a powerful blend of capabilities focused on supporting small and mid-sized biotech and pharmaceutical companies with their innovative research. Our companies share strong cultural values, anchored by a commitment to high quality and personalized customer service. Together, we’re focused on growing and enhancing our services to build an industry-leading company specializing in complex therapeutic areas, including oncology, cell and gene therapy, and rare treatments,” said Mark A. Goldberg, M.D., executive chairman, CATO.
Philine van den Tol, CEO, SMS-oncology, added, “Coming together with CATO is an important step toward our objective of providing clients with a broader set of solutions supported by the high-touch service that they expect from us. We can now offer our clients an expanded geographic footprint in the United States and Canada, as well as additional access to valuable drug development and regulatory expertise. We’re especially excited to engage CATO’s expertise in working with the FDA.”
Ms. Van den Tol and the management team will continue to lead the company’s operations. Dr. Goldberg will serve as executive chairman of the combined entity. CATO and SMS-oncology will operate under their respective brands until the transition to their new name, CATO SMS, is complete.
CATO’s merger with SMS-oncology is the latest step in the company’s strategic expansion since Water Street Healthcare Partners and JLL Partners invested in the company last year. The health care investors recently announced the acquisition of THREAD, a provider of innovative technology that enables virtual research. CATO can engage THREAD on opportunities where clients want to leverage its platform to modernize their clinical studies and registries through technology-enabled interactions.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-10-28 13:47:462019-10-29 13:51:17Cato Research and SMS-oncology merge← #nieuws
ProQR
Therapeutics, a company dedicated to changing lives through the creation of
transformative RNA medicines for severe genetic rare diseases, today announced
the closing of its previously announced underwritten public offering of
9,090,909 ordinary shares at a price to the public of $5.50 per
share. All of the shares are being offered by ProQR. The closing
included the full exercise of the underwriters’ option to purchase up to
1,363,636 additional ordinary shares at the public offering price, less
underwriting discounts and commissions. Gross proceeds from the offering
totaled approximately $57.5 million, before deducting underwriting discounts
and commissions and offering expenses.
Citigroup Global Markets and Evercore ISI acted as joint bookrunners for the offering. Cantor Fitzgerald & Co. and JMP Securities acted as lead managers, with Chardan and Kempen acting as co-managers.
Afgelopen week reageerde VWS minister Bruno Bruins, mede namens de minister van EZK, op de visie van Tweede Kamerlid Pia Dijkstra “Voor één gezonde Europese geneesmiddelenmarkt”, die zij vlak voor de Europese verkiezingen de ether in slingerde. En dat doet Bruins verdienstelijk. In zijn Kamerbrief legt de minister uit hoe de vork in de steel zit als het gaat om transparantie, intellectueel eigendom en andere stimuleringsmaatregelen, marktmacht, maximumprijzen en Europese samenwerking. De inzet van zijn beleid: innovatie stimuleren en belonen, misbruik gericht aanpakken.
Biotech ambassadeur Hans Schikan schoof recent aan bij BNR-radioprogramma ‘Zakendoen met’, naar aanleiding van de succesvolle investeringsronde van Pharvaris. Het biotech bedrijf haalde 66 miljoen dollar op voor de ontwikkeling van een pil tegen erfelijk angio-oedeem. In het interview legt Hans op de hem kenmerkende heldere en enthousiaste wijze uit hoe de biotech sector in elkaar steekt. Zo gaat hij in op het lange, kostbare en risicovolle traject van geneesmiddelenontwikkeling, de cruciale rol van octrooien daarin en over de belangrijke balans tussen waarde voor aandeelhouders en voor patiënten. Een luistertip!
Lees en luister hier een deel van het interview terug
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-10-22 11:33:112019-10-22 11:33:13Luistertip: Hans Schikan bij BNR← #nieuws
Vanaf 1 januari 2020 is Clémence Ross-van Dorp, voormalig
staatsecretaris van VWS, ambassadeur voor het Actieprogramma ‘Nieuwe kansen
voor Topsector Life Sciences & Health’ (LSH). Zij doet dat namens minister
Bruno Bruins van Medische Zorg en Sport en staatssecretaris Mona Keijzer van
Economische Zaken en Klimaat.
De aanleiding voor het opzetten van het Actieprogramma is
de komst van het Europees Geneesmiddelen Agentschap (EMA) naar Nederland begin
2019. Als ambassadeur zal Ross-van Dorp zich inzetten om de economische en
maatschappelijke kansen die de komst van de EMA biedt optimaal te verzilveren
en zo de Nederlandse LSH-sector te versterken. Dit najaar zal Ross-van Dorp starten
met voorbereidende activiteiten op haar rol als ambassadeur: zo zal ze alvast
kennis gaan maken met de relevante stakeholders.
Ross-van Dorp is voorzitter van de Long Alliantie Nederland. Ook is ze bestuurder bij de Stichting Agora en vervult zij diverse toezichthoudende functies, waaronder bij de Universiteit Twente en het Prinses Máxima Centrum voor kinderoncologie. Ross-Van Dorp was van 2002 tot 2007 staatssecretaris van het ministerie van Volksgezondheid, Welzijn en Sport.
Pepscan’s GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides. The doubled GMP production capacity enables Pepscan to guarantee short production timelines. It also gives clients the benefit of collaborating with a single expert partner on the way from R&D to the clinic, resulting in maximum efficiency while also saving time. Specifically, researchers active in personalized peptide medicine, where both timelines and flexibility are key, will benefit from these new developments.
Hans de Backer, CEO of Pepscan, explains the
new capacity additions. “Earlier this year, we started producing GMP peptides
for clinical studies phases 1 and 2, which made it possible to provide peptides
for purposes beyond R&D: directly for the benefit of patients. Our new
production line, consisting of a new synthesizer, a preparative HPLC and
lyophilizer in our cleanroom, and the strengthened QMS and process
documentation that were put in place for this, have proven to facilitate the efficient
execution of the process. Using this proven concept, we have now doubled the complete
production line.” Current production includes both therapeutic peptide projects
as well as personalized peptide medicine projects (e.g. neoantigen vaccines).
“Given our role in the field of personalized
medicine, short and reliable delivery times are crucial,” adds Hanne Kho, Chief
Operations Officer of Pepscan. “This demands a set of rigorous processes and a
certain level of flexibility that we, together with outstanding product
quality, are able to deliver. I’m very proud that the recent GMP customer
audits that were conducted have confirmed this.”
De Backer continues, “Doubling our GMP production capacity is a major milestone that transforms our newly developed GMP capabilities into a solid pillar of our peptide services portfolio. In the last 25 years, we have built extensive knowledge and a reputation for our expertise in developing and producing peptides, specifically constrained peptides. I’m glad that we are now able to use this expertise to provide peptides for purposes beyond R&D: directly for the benefit of patients.”
The European
Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan
agreement to support the development of ISA’s
therapy for cancers caused by the Human Papillomavirus type 16 (HPV16). The EIB’s financing is supported under the “Infectious
Diseases Finance Facility” (IDFF) of the InnovFin
– EU-finance for innovators programme, which
is financed from the EU’s research and
innovation programme Horizon 2020.
Persistent HPV16
infection can cause cervical, head & neck and anogenital cancers. These
cancers can be severe and life-threatening, with low overall survival rates of
advanced stages. Cervical cancer is the 2nd most common cancer in
women aged 15 to 44 years in Europe, with HPV16 causing over 35,000 new cases
and 15,000 deaths each year. The virus is also a major cause of oropharyngeal
cancer with over 25,000 new cases and 12,000 deaths each year in Europe alone1.
ISA
Pharmaceuticals has developed a novel therapy, ISA101b, which targets
HPV16-positive cancers through the specific activation of the patient’s own
immune system. The treatment has proven to be safe with no serious side
effects, and has demonstrated substantial benefit for patients, when used in
addition to current treatment in advanced stages of the head & neck cancer
and cervical cancer. ISA101b represents a unique and innovative treatment
modality. It is designed to fight HPV16 driven premalignant conditions and
early stage cancers as monotherapy, and metastatic malignancies when given
together with standard of care.
“ISA’s lead product is at a very exciting final
stage of development. This loan from the EIB will help accelerate the programme
all the way to our ultimate goal of making ISA101b available to all patients
suffering from HPV16-induced cancers,” said Gerben Moolhuizen, CEO of
ISA Pharmaceuticals.
“I am very
pleased that we can actively contribute to combating cancer and its causes as a
financial institution, thanks to the support of the European Commission’s
InnovFin programme. After financing projects for research into the Zika virus
and Ebola vaccines, this human papillomavirus project is one that we gladly
participate in. The EIB has significantly increased its support for projects
related to innovation in the health sector recently, and we see the ISA project
as a very promising one with significant potential benefits for many patients.”
said Ambroise Fayolle, Vice-President of EIB.
Through the
support of IDFF, the EIB can provide stable long-term funding with a flexible
repayment and interest structure, limiting the cash outflow from the company
and thereby enabling it to focus on investing in innovation and growth.
Carlos Moedas, European Commissioner forResearch, Science and Innovation, said: “With more people living longer, cancer rates are increasing everywhere. Europe has 9% of the world’s population but a 23% share of the global cancer burden. This is why we support the development of new drugs to treat life-threatening diseases such as cancer through the EU research and innovation programme, Horizon 2020.”
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00hollandbiohttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svghollandbio2019-10-15 22:24:482019-10-15 22:24:50ISA Pharmaceuticals receives EUR 20m loan from European Investment Bank